Stock Price Movement and Market Context
On 25 Feb 2026, Concord Biotech Ltd’s stock touched Rs.1056.75, its lowest level in the past year, after four consecutive days of decline. The stock showed some recovery intraday, gaining 5.51% to reach Rs.1137.55, and closed with a day change of +4.78%. Notably, the price remains above its 5-day moving average but continues to trade below its 20-day, 50-day, 100-day, and 200-day moving averages, signalling a longer-term downtrend.
Meanwhile, the broader market environment was positive, with the Sensex rising 0.73% to 82,826.28 points, just 4.02% shy of its 52-week high of 86,159.02. Mega-cap stocks led the rally, although the Sensex itself is trading below its 50-day moving average, which remains above the 200-day moving average, indicating mixed technical signals.
Financial Performance and Valuation Metrics
Concord Biotech Ltd’s financial indicators have contributed to the stock’s subdued performance. The company’s operating profit has contracted at an annualised rate of -0.34% over the past five years, reflecting challenges in sustaining growth momentum. The last three consecutive quarters have reported negative results, with the latest half-year Return on Capital Employed (ROCE) at a low 23.48%.
Quarterly Profit Before Tax (PBT) excluding other income stood at Rs.79.46 crores, down 15.9% compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) for the quarter was Rs.66.90 crores, a decline of 17.4% relative to the prior four-quarter average. These figures underscore a contraction in profitability over recent periods.
The company’s Return on Equity (ROE) remains relatively high at 17.7%, but this is juxtaposed with a Price to Book Value ratio of 6.1, indicating a valuation that is considered expensive relative to its book value. Despite this, the stock is trading at a discount compared to its peers’ historical average valuations, reflecting market caution.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Long-Term and Recent Performance Trends
Over the past year, Concord Biotech Ltd’s stock has declined by 30.58%, significantly underperforming the Sensex, which gained 11.00% over the same period. The stock’s 52-week high was Rs.2149.90, highlighting the extent of the recent correction. Furthermore, the company’s profits have fallen by 3.5% in the last year, reinforcing the subdued earnings environment.
In addition to the one-year underperformance, the stock has lagged behind the BSE500 index over the last three years, one year, and three months, indicating persistent challenges in delivering shareholder returns relative to the broader market.
Operational Efficiency and Capital Structure
Despite the financial setbacks, Concord Biotech Ltd maintains a strong management efficiency profile, with a high ROE of 19.17%. The company’s capital structure is conservative, with an average Debt to Equity ratio of zero, reflecting a debt-free balance sheet. Promoters remain the majority shareholders, providing stability in ownership.
Holding Concord Biotech Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Metrics
Concord Biotech Ltd’s current Mojo Score stands at 28.0, with a Mojo Grade of Strong Sell, upgraded from Sell on 23 Feb 2026. The company’s Market Cap Grade is 3, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector. The stock’s recent price action and financial results have contributed to this grading, highlighting concerns over growth and profitability.
While the stock outperformed its sector on the day of the new low, the broader trend remains negative, with multiple moving averages indicating resistance levels above the current price. The company’s valuation metrics suggest a premium pricing relative to book value, despite the recent price correction.
Conclusion
Concord Biotech Ltd’s stock reaching a 52-week low of Rs.1056.75 reflects a combination of subdued earnings performance, valuation considerations, and broader market dynamics. The company’s declining profitability over recent quarters and negative growth trends have weighed on investor sentiment, despite a strong management efficiency profile and a debt-free balance sheet. The stock’s performance contrasts with the broader market’s positive momentum, underscoring sector-specific pressures within Pharmaceuticals & Biotechnology.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
